Clinical trial
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
NCT00097825 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00097825 |
|---|---|
| Title | Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men |
| Official title | Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Zoledronic Acid |
| Enrollment | 288 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Dec 1, 2004 |
| Last update posted | Apr 27, 2012 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: